NewGenIvf swings to net loss of US$8.08 million for six months ended June 30, 2026; revenue falls 5% to US$1.92 million
NIVF•NewGenIvf reported revenue of US$1.92 million for the six months ended June 30, 2026, down 5% year over year, and a net loss attributable to shareholders of US$8.04 million, versus net income of US$724,975 a year earlier.
1. Six-month results
NewGenIvf posted revenue of US$1.92 million for the six months ended June 30, 2026, down 5% year over year. Its net loss attributable to shareholders widened to US$8.04 million from net income of US$724,975 a year earlier.
2. Losses and assets
Operating loss increased to US$3.55 million, while total other income (expenses), net, deepened to a loss of US$8.08 million. Total assets rose to US$36.44 million at June 30, 2026, and cash and cash equivalents increased to US$1,023,789.
